Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Syndax Pharmaceuticals Inc (SNDX)
NASDAQ:SNDX
RESEARCH TOOLSreports
Syndax Pharmaceuticals (SNDX) Stock Price & Analysis
568 Followers
SNDX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$11.22 - $25.34
Previous Close$23.48
Volume825.37K
Average Volume (3M)1.06M
Market Cap
$2.00B
Enterprise Value$1.56B
Total Cash (Recent Filing)$434.58M
Total Debt (Recent Filing)$1.37M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Aug 05, 2024EPS Estimate
-$0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.22
Shares Outstanding84,987,060
10 Day Avg. Volume1,229,637
30 Day Avg. Volume1,059,637
Standard Deviation0.17
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)3.07
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-10.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-6.31
Forecast
1Y Price Target
$30.67Price Target Upside25.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Syndax Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsSyndax announced that 71% of patients that had a composite complete remission and evaluable data attained MRD-negative status; seven patients underwent hematopoietic stem cell transplant while in remission following treatment.
FDA DesignationRevumenib previously received Breakthrough Therapy Designation from the FDA for the treatment of adult and pediatric patients with relapsed or refractory acute leukemia harboring a KMT2A-rearrangement.
Future PotentialSyndax is likely to launch its first two products this year, both in areas of high unmet needs, with opportunities for commercial synergies.
Bears Say
Execution And CompetitivenessThere are concerns regarding both execution as a new commercial entity as well as longer-term competitive questions.
Financial PerformanceThe FY24 EPS estimate is being decreased to ($3.88) from ($3.63), and the FY24 revenue estimate is being lowered to $8.9M from $36.2M.
R&D Expenses1Q24 R&D expense was $56.5M versus $34.1M in 1Q23.
---
Ownership Overview
1.06% Insiders
21.71% Mutual Funds
13.23% Other Institutional Investors
64.01% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SNDX FAQ
What was Syndax Pharmaceuticals Inc’s price range in the past 12 months?
Syndax Pharmaceuticals Inc lowest stock price was $11.21 and its highest was $25.34 in the past 12 months.
What is Syndax Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Syndax Pharmaceuticals Inc’s upcoming earnings report date?
Syndax Pharmaceuticals Inc’s upcoming earnings report date is Aug 05, 2024 which is in 14 days.
How were Syndax Pharmaceuticals Inc’s earnings last quarter?
Syndax Pharmaceuticals Inc released its earnings results on May 08, 2024. The company reported -$0.85 earnings per share for the quarter, beating the consensus estimate of -$0.979 by $0.129.
Is Syndax Pharmaceuticals Inc overvalued?
According to Wall Street analysts Syndax Pharmaceuticals Inc’s price is currently Undervalued.
Does Syndax Pharmaceuticals Inc pay dividends?
Syndax Pharmaceuticals Inc does not currently pay dividends.
What is Syndax Pharmaceuticals Inc’s EPS estimate?
Syndax Pharmaceuticals Inc’s EPS estimate is -$0.91.
How many shares outstanding does Syndax Pharmaceuticals Inc have?
Syndax Pharmaceuticals Inc has 84,987,060 shares outstanding.
What happened to Syndax Pharmaceuticals Inc’s price movement after its last earnings report?
Syndax Pharmaceuticals Inc reported an EPS of -$0.85 in its last earnings report, beating expectations of -$0.979. Following the earnings report the stock price went down -3.451%.
Which hedge fund is a major shareholder of Syndax Pharmaceuticals Inc?
Among the largest hedge funds holding Syndax Pharmaceuticals Inc’s share is Woodline Partners LP. It holds Syndax Pharmaceuticals Inc’s shares valued at 37M.
---
Syndax Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.67 (25.80% Upside)
$30.67 (25.80% Upside)
Blogger Sentiment
Bullish
SNDX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $25.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 8.6%
Last 30 Days ▲ 8.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.00%
12-Months-Change
Fundamentals
Return on Equity
-51.89%
Trailing 12-Months
Asset Growth
18.09%
Trailing 12-Months
Company Description
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
---
SNDX Company Deck
---
SNDX Earnings Call
Q1 2024
0:00 / 0:00
---
SNDX Stock 12 Month Forecast
Average Price Target
$30.67
▲(25.80% Upside)
Technical Analysis
Best Analysts Covering SNDX
1 Year
1 Year Success Rate
6/7 ratings generated profit
1 Year Average Return
+29.67%
reiterated a buy rating last month
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +29.67% per trade.
---